Hogan Lovells advises Perspective Therapeutics on its US$175 million underwritten registered offering of equity securities

Perspective is a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body.

Perspective announced the pricing of an underwritten registered offering of 39,576,088 shares of its common stock at an offering price of US$3.79 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 6,598,046 shares of its common stock at a price of $3.789 per pre-funded warrant, which represents the per share offering price for the common stock less the US$0.001 per share exercise price for each such pre-funded warrant.

The aggregate gross proceeds from this offering were US$175 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the offering.

Piper Sandler, UBS Investment Bank, Oppenheimer & Co., Truist Securities and LifeSci Capital acted as joint book-running managers for the offering.

More information on the transaction can be found here.

The Hogan Lovells deal team was led by partners Stephen Nicolai (Philadelphia) and Andrew Strong (Houston), senior associates Amanda Brown and Tyler Glass (both Philadelphia), and associate Kayvon Paul (Philadelphia).